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Abstract
Background/Aims: Many anti-fibrotic drugs with high in vitro efficacies fail to produce significant effects in vivo. The aim of
this work is to use a statistical approach to design a numerical predictor that correlates better with in vivo outcomes.
Methods: High-content analysis (HCA) was performed with 49 drugs on hepatic stellate cells (HSCs) LX-2 stained with 10
fibrotic markers. ,0.3 billion feature values from all cells in .150,000 images were quantified to reflect the drug effects. A
systematic literature search on the in vivo effects of all 49 drugs on hepatofibrotic rats yields 28 papers with histological
scores. The in vivo and in vitro datasets were used to compute a single efficacy predictor (Epredict).
Results: We used in vivo data from one context (CCl4 rats with drug treatments) to optimize the computation of Epredict. This
optimized relationship was independently validated using in vivo data from two different contexts (treatment of DMN rats
and prevention of CCl4 induction). A linear in vitro-in vivo correlation was consistently observed in all the three contexts. We
used Epredict values to cluster drugs according to efficacy; and found that high-efficacy drugs tended to target proliferation,
apoptosis and contractility of HSCs.
Conclusions: The Epredict statistic, based on a prioritized combination of in vitro features, provides a better correlation
between in vitro and in vivo drug response than any of the traditional in vitro markers considered.
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Introduction
Liver fibrosis, a disease of excessive extracellular matrix (ECM)
accumulation, is a common downstream response to repeated liver
injury, caused by factors such as hepatitis B or C virus infection,
excessive alcohol consumption, non-alcoholic steatohepatitis
(NASH), autoimmune hepatitis, or drugs and toxins such as
azathioprine [1], D-galactosamine [2] or low doses of paracetamol
[3]. In current clinical practice, the most effective anti-fibrotic
treatment is indirect: to target the underlying cause(s) of injury, as
removal of primary insults may lead to spontaneous regression of
fibrosis. For example, lamivudine, which blocks hepatitis B virus
replication, can result in fibrosis resolution [4]. However, fully
activated hepatic stellate cells (HSCs), besides being a major source
of fibrotic ECM [5], also secrete a broad range of chemokines and
cytokines for self-perpetuating fibrosis in the absence of primary
insults [6]. As a result, indirect treatment by removing the
underlying irritant is not effective in a significant population of
liver fibrosis patients.
Current drug discovery efforts for direct anti-fibrotic therapies
have primarily targeted activated HSCs. Over recent years, the
focus in drug discovery research has shifted from cell-free
approaches based on molecular targets, to cell-based systems-
biology based approaches, in an effort to increase success rates and
reduce the overhead costs of drug development [7]. Since multiple
complex pathways are involved in fibrogenesis, it is important to
study the anti-fibrotic effects of a drug in the cellular context.
Several high-throughput in vitro screenings have been performed
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previously on HSCs or fibroblast cells. Xu et. al. (2007) established
a quantitative screening platform based on TGF-b1 dependent
fibroblast nodule formation [8]. Using this system, 8 out of 21
herbal extracts were found to have anti-fibrotic activities [9]. In
other studies, HSC proliferation and apoptosis were used to assess
the direct effects of drugs on HSC [10,11]. Collagen expression is
another indicator commonly used in high-throughput systems
[12,13]. These studies together with conventional low-throughput
in vitro and in vivo studies have identified a diverse group of positive
chemicals. The most promising ones, such as losartan, pioglitazone
and Fuzheng Huayu tablets, have entered phase IV clinical trials
[14].
Despite numerous efforts in anti-fibrotic drug discovery, there is
no anti-fibrotic drug approved by the U.S. Food and Drug
Administration. Many candidate drugs for fibrosis have failed in
preclinical or clinical trials. One of the reasons is that in vitro data
have poor correlation with in vivo drug effects due to the
complicated pathophysiological background of hepatic fibrogen-
esis. As a result, drugs with high in vitro efficacies based on simple
biochemical assays may fail to produce significant in vivo effects
[15]. Despite the different levels of complexity between the in vitro
and in vivo systems, previous studies from other fields such as drug
dissolution [16,17], have demonstrated that optimized design of in
vitro systems can result in better correlation with in vivo data
[18,19].
In the present study, we quantitatively assessed and compared
end-point anti-fibrotic drug responses from in vitro and in vivo
models. A high-content analysis (HCA) system was established that
provides a strong positive correlation with the in vivo drug
responses. A drug efficacy predictor (Epredict) was computed and
optimized to have a high positive correlation with the in vivo drug
efficacy (Ein vivo) extracted from studies using rat carbon
tetrachloride (CCl4) treatment models. This positive correlation
was validated with two additional validation datasets from rat
CCl4 preventive and dimethylnitrosamine (DMN) treatment
models. Moreover, a linear in vitro-in vivo relationship was
consistently observed in all three datasets, suggesting that the
Epredict value can also be used to rank drug efficacy and generate
predictions. Drugs with higher Epredict were observed to exert their
primary effects by targeting HSC proliferation, apoptosis or
contractility, which are consistent with previous anti-fibrosis
strategies.
Materials and Methods
Cell culture
The human HSC cell line LX-2 was obtained as a generous gift
from Dr. Scott Friedman (Mount Sinai Hospital, NY). The cells
were cultured in Dulbecco’s modified eagle medium with
1000 mg/L glucose (Biopolis Shared Facilities, Singapore) and
10% heat inactivated fetal bovine serum (Gibco, Grand Island,
NY, USA) and incubated in 37uC in a humidified atmosphere with
95% air/5% carbon dioxide.
Drug preparation
45 anti-fibrotic drugs and 4 non-specific control compounds not
related to fibrosis were included in this study. The stock solution of
each drug was prepared by dissolving the drug in dimethyl
sulfoxide (Sigma-Aldrich, St Louis, MO, USA) at the maximum
solubility of a drug unless the solvent is specifically indicated in the
manufacturer’s information sheet. The highest working concen-
tration of each drug was determined as the IC50 value from a cell
viability assay (Table S1) and was dispensed in the second column
of a 96-well plate (Nunc, Roskilde, Danmark). 10 other working
concentrations were prepared by 2-fold serial dilution from the
highest concentration in the same 96-well plate from column 3 to
column 12. The first column of each plate was used as a drug-free
control column.
Drug treatment
LX-2 cells were seeded in 96-well glass-bottom optical plates
(Matrical bioscience, Spokane, Washington). The seeding density
was 0.007 million in 100 ml medium per well, allowing cells to
reach 70% confluence after a 3-day incubation. 24 hours after cell
seeding, the culture medium was removed and fresh medium with
drug was added and the cells were further incubated for 48 hours
before the viability assay or staining was performed.
Cell viability assay
Cell viability was evaluated using 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)2-(4-sulfophenyl)-2H-tetrazolium (MTS),
according to the manufacturer’s instructions (CellTiter 96 Aqueous
One Solution Cell Proliferation Assay, Promega). MTS reagent was
prepared by mixing minimum essential medium (Gibco, Grand
Island, NY, USA), FBS and CellTiter One solution at a ratio of 9:1:2
just before the assay. 120 ml of the prepared reagent was added to
each well and the plates incubated for 60 minutes in a 37uC
incubator. At the end of the incubation, 100 ml of the medium was
transferred to a new 96-well plate and the absorbance read at
490 nm. All readings were corrected with blank controls (MTS
reagent incubated for 1 hour in 37uC in empty wells). All conditions
were duplicated per experiment and all experiments were performed
twice. The average values were used to determine the IC50 values
and the highest drug working concentrations were set to be close to
the IC50 values.
Cell staining
Ten markers of fibrosis (Table S3) were included in this study
and they were studied using 7 staining sets. We used 5 Cellomics
Hitkits to track changes in cell proliferation (BrdU cell prolifer-
ation kit), apoptosis (Multiparameter apoptosis 1 kit and Caspase 3
activation kit), cell shape (Multiparameter apoptosis 1 kit),
oxidative stress (Oxidative stress 1 kit) and cytokine activities
(Smad3 and phospho-CREB activation kit). Five samples and their
duplicates were separately stained using the 5 kits. The staining
steps were carried out according to the manufacturer’s instructions
(Thermo Fisher Scientific, Rockford, Illinois) with the exception of
the nuclear staining procedure. For all the staining protocols in this
study, nuclei were separately stained (Hoechst 33258 diluted
1:1000) after secondary antibody staining and incubated for
10 minutes under room temperature before the cells were washed
and subjected to image acquisition.
In addition, two samples and their duplicates were separately
stained with collagen type III antibody or double-stained with
matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of
metalloproteinases-1 (TIMP-1) antibodies. LX-2 cells were fixed
in pre-warmed 3.7% paraformaldehyde (Sigma-Aldrich, St Louis,
MO, USA) in 37uC for 10 minutes and permeabilized with 1%
Triton X-100 (Thermo Fisher Scientific, Rockford, Illinois) at
room temperature for another 10 minutes before blocking with
10% BSA (Sigma, Canada). After 30 minutes blocking, the cells
were incubated with either anti-collagen III antibody (diluted
1:100, Santa Cruz Biotechnology) or a mixture of the MMP-2 and
TIMP-1 antibodies (anti-MMP-2 antibody was diluted 1:1000,
Santa Cruz Biotechnology; anti-TIMP-1 antibody was diluted
1:100, Santa Cruz Biotechnology) for 2 hours at room tempera-
ture. After washing, the cells were incubated with fluorescein-
conjugated affinity purified anti-rabbit IgG (H&L) (goat) (diluted
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1:200, Rockland, USA) or Texas red conjugated affinity purified
anti-mouse IgG (H&L) (donkey) (diluted 1:200, Rockland, USA) at
room temperature for 1 hour, protected from light. Hoechst
33258 (diluted 1:1000) was subsequently added for 10 minutes
before the cells were washed and subjected to image acquisition.
Image acquisition
Images were acquired using Cellomics ArrayScan VTI (Thermo
Scientific) controlled by vHCSTM Scan software version 6.1.4
(Build 6133). All images were taken with a LD Plan_Neofluar 206
air objective. 16 high-resolution images (102461024 pixels) were
taken per well, which captured about 1000 to 2000 cells per
experimental condition.
Image processing and statistical analysis
There are about 100 cells captured per image. Image
segmentation and feature extraction were performed with a
modified evolving generalized Voronoi diagrams algorithm [20],
in which individual cells were identified and 25 or 16 cytological
features were extracted per cell, for samples with 3-channel or 2-
channel staining respectively. These features described cellular
shape, protein distribution and content. A complete list of
cytological features is shown in Table S2. The efficacy predictor
(Epredict) was computed using Matlab R2009a with image
processing and statistical toolboxes (material S1). In short, the
raw data from in vitro experiments consists of multiple dimensions
that include multiple cells in each treatment condition, drug
concentrations, cellular features, and fibrotic markers. We reduced
the data complexity in a 3-step statistical process (described in the
material S1) and derived a SAUC value per fibrotic marker per
drug. Subsequently, the Epredict score was computed by a linear
combination of the SAUC values. The optimized weight for each
fibrotic marker in the linear combination was calculated and
validated independently with the training and validation in vivo
data sets respectively (described in the result section 4).
Automation
During activation, HSCs undergo phenotypic changes such as
increasing proliferation and ECM production (Fig. 1A) [21]. Many of
these changes are potential therapeutic targets. We followed 5 such
changes (Fig. 1B) with 10 chosen markers (Fig. 1C) using an HCA
system that can be divided into 4 components: sample preparation,
automated image acquisition, image processing and statistical analysis
(Fig. 1D). All the sample preparation procedures including cell
culture, drug preparation, drug treatment, cell viability assay and
immunofluorescence staining were automated using a JANUSTM
automated liquid handling system (Perkin Elmer).
Results
We have developed an HCA-based quantitative assessment
screen that uses the Epredict value to correlate in vitro and in vivo anti-
fibrotic drug responses. Subsequently the Epredict value was used in
two applications: predicting in vivo drug efficacy from in vitro data,
and determining the cellular pathways that are common among
the more effective anti-fibrotic drugs.
All 10 markers of fibrosis captured drug-induced changes
in LX-2 cells
In HCA, cells were treated with the 49 drugs at 11
concentrations, stained for 10 markers of fibrosis (Table S3), and
imaged using automated microscopy. Cellular features such as the
extent of changes in shape and marker intensity were then
quantified for assessing the anti-fibrotic efficacies of the drugs.
Drug-induced changes can be clearly detected in the datasets;
for example, glycyrrhizin caused an increase in apoptosis (i.e.,
increase in the caspase 3 level and decrease in the mitochondrial
membrane potential DYm, measured by Mitotracker Red) and a
decrease in four other markers: proliferation (i.e., bromodeoxyur-
idine (BrdU) positive cells), oxidative stress (i.e., dihydroethidium
(DHE) intensity), collagen (i.e., collagen type III intensity), and
TIMP-1 (i.e., TIMP-1 intensity). The Smad3 marker for TGF-b1/
fibrosis signaling was also studied. The ratio between nuclear and
cytoplasmic intensities for Smad3 decreased with drug treatment,
demonstrating reduced nuclear translocation and reduced activa-
tion of the protein. This suggests that glycyrrihizin can down-
regulate the TGF-b1 signaling pathway. Furthermore, the total
Smad3 level increased in cells treated with anti-fibrotic drugs;
previous work showed that Smad3 is required for inhibiting HSC
proliferation [22] (images in Fig. 2A).
Changes in fibrotic markers in vitro are consistent with in
vivo drug response
We used a modified evolving generalized Voronoi diagrams
algorithm to identify individual cells from the images. 5 nuclear
features and 11 cytoplasmic features per marker were extracted
from each cell. These features quantitatively described cellular
characteristics such as cell shape, protein expression levels and
protein localization in the nucleus and cytoplasm (Table S2).
The cellular features from cells treated with various drug
concentrations were normalized and combined to create a single
SAUC score per fibrotic marker per drug (material S1). The SAUCs
vary positively with the anti-fibrotic effects of a drug on the 10
markers. Briefly, we converted the cellular feature values into a
Kolmogorov-Smirnov score [23] or ratio depending on whether a
feature value has a unimodal or bimodal distribution. Both
Kolmogorov-Smirnov score and ratio vary from -1 to 1 and the
combined result was termed the KR value (Fig. 2A). A negative KR
value represents a decreasing feature value (e.g. intensity)
compared with the control; while a positive one represents
increasing feature value. The KR values exhibit drug concentra-
tion-dependent changes shown by the color intensities in the
heatmaps. The extent of changes of cells stained with a particular
marker is then computed from the KR values and termed the
SAUC score, which is the sum of the sign corrected area under the
curve from a plot of KR values versus drug concentrations. The
sign of the SAUC value was corrected to increase if the drug
exhibits anti-fibrotic effects (material S1).
Each drug has 10 SAUC values corresponding to the 10 markers
of fibrosis. In vitro drug effects can be assessed based on these values,
and the results could be correlated to in vivo response. For example,
oxymatrine exhibited a higher efficacy than colchine, as oxymatrine
treated rats had lower histopathological scores, smaller collagen
area in the liver tissue, and lower concentrations of the serum
markers such as hyaluronic acid and procollagen III compared with
colchicine treated rats [24]. From our HCA results, the SAUC values
for at least half of the markers showed a higher value for oxymatrine
than colchicine (Fig. 2B). In order to have a more quantitative
comparison of the drug efficacies, our goal is to consolidate the 10
SAUC values into a single index as a drug efficacy predictor that is
positively correlated with an in vivo drug efficacy index.
An in vivo anti-fibrotic drug efficacy index ranks drugs
based on their in vivo effects
Different weights will be assigned to the SAUC values to reflect
the relative importance of each of the markers towards the overall
efficacy. The weights should be chosen so that the overall index
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can reflect the in vivo response of a drug. Before we can do that, we
need a numerical measure of the in vivo drug efficacy. Previous
work that involved multiple drugs in a single in vivo study carried
out the drug efficacy comparison by assessing the extent of fibrosis
in liver biopsy samples, as well as the level of surrogate serum
markers for liver fibrosis such as alanine aminotransferase (ALT)
and aspartate aminotransferase (AST). Such an approach does not
summarize the experimental results into a drug efficacy index for
direct comparison and ranking of drugs within a single in vivo study
or between studies. Here we analyzed the literature and an in vivo
drug efficacy scoring system was computed based on histological
scores.
Most of the in vivo studies reported in the literature were carried
out in rat models. Although numerous such papers are available,
there is no standard method to compare these results. To compare
the in vivo drug efficacies, we have established an in vivo index based
on pathologist-graded histological scores, which are considered a
gold standard for quantifying the extent of fibrosis. A systematic
search was performed on the reported in vivo effects of all 49 drugs
on hepatofibrotic rats. The search yielded 28 papers from 1986 to
2009 with pathologist-graded histological scores, using CCl4,
TAA, DMN, cisplatin, pig serum, high calorie diet or bile duct
ligation induced fibrotic rats (Table S4). These studies can be
further divided into preventive or treatment models, depending on
whether a drug is given since the first injection of hepatotoxin or
after liver fibrosis has been established.
To define a formula for in vivo drug efficacy, we attempted to
combine the histological score of fibrotic animals without drug
treatment (Sc) and the histological score of drug treated animals
(St). The in vivo efficacy of a drug is expected to be positively
correlated with the changes in histological scores between the
control and drug-treated biopsy samples (Sc - St). In addition, the
drug efficacy may also be positively dependent on the fibrosis
severity, as there are observations that individuals with more
advanced fibrosis are less likely to respond to treatment, hence
these patients require drugs with higher efficacy [15]. A
Figure 1. Principle for evaluation of anti-fibrotic drug efficacy. (A) Phenotypic changes of hepatic stellate cells during activation. (B) Potential
sites for therapeutic interventions and (C) markers that track the effects of the interventions. (D) The high-content analysis system with 4 core
components (sample preparation, automated image acquisition, image processing and statistical analysis).
doi:10.1371/journal.pone.0026230.g001
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quantitative in vivo efficacy index (Ein vivo) was computed as shown
below:
Ein vivo~Sc|(Sc{St)
Both Sc and St were linearly converted to a 0–4 scale, which is a
commonly used range for histological scores in several fibrosis
scoring systems such as Metavir, Knodell and Ludwig [25]. If
histological scores of a drug from multiple studies were available,
the highest Ein vivo value was chosen.
The severity of fibrosis induced by different hepatotoxins varies
(e.g. Ein vivo for silymarin is 0.8 for DMN treatment model, 3.1 and
6 for CCl4 treatment and preventive models); hence the indices are
only comparable within the same fibrosis model. Subsequent
correlation analysis was conducted using studies with long-term
(.3 week) drug treatment, and fibrotic models with at least 3
drugs. The in vivo results satisfying these criteria are summarized in
Table 1. CCl4 preventive and treatment models have 5 drugs in
common; we found that three of these drugs: silymarin, malotilate
and pioglitazone have the same relative ranking in both models
while PCN and taurine didn’t follow the ranking. Interestingly
subsequent analysis showed that both PCN and taurine were
outliners in the in vitro-in vivo correlation plots.
The calculated Ein vivo is an attempt to capture the therapeutic
efficacy of drugs on human patients. There are relatively few studies
suitable for directly comparing drug effects on human patients due
to variations in experimental design. In one example, two similar
clinical studies using colchicine and silymarin on patients with
cirrhosis due to any primary insults showed that colchicine led to
75% 5-year survival rate [26], while silymarin led to 58% 4-year
survival rate [27]. Ein vivo agrees with these reports that colchicine has
a higher value (5.7) than silymarin (0.8) (Table 1).
An in vitro efficacy predictor Epredict that positively
correlates with the Ein vivo value of a drug
The SAUC values for the majority of drugs showed a weak
positive correlation with the Ein vivo (Fig. S1: DYm, TIMP-1, DHE,
pCREB and Smad3). We investigated if we could further enhance
this correlation by applying weights (0, 1 or 2) to the SAUC values.
0 indicates no contribution of the marker to the positive
correlation; while 2 indicates strong contribution of the marker
to the positive correlation. The Ein vivo values from the CCl4
treatment model were used as the training dataset to find the
optimized weights.
All possible linear combinations of the 3 weights with 10
markers (310 combinations) were subjected to the Spearman’s rank
Figure 2. Images and quantification of the changes of LX-2 with drug treatment. (A) The cells are treated with or without 13.3 mM
glycyrrhizin as indicated for 48 hours. Nuclei are stained (blue) in all the images; while 10 fibrotic markers are represented with either red or green
colors. Heatmaps show the variations of the KR values for each of the cytological features (y-axis) with increasing drug concentrations from 0 mM to
13.3 mM (x-axis). Cytological features with similar variations are clustered together in the heatmaps. Drug-induced concentration-dependent changes
can be clearly detected in the graphs. Numbers in the heatmaps are the SAUC values. (B) The SAUC values for drugs colchicine and oxymatrine.
doi:10.1371/journal.pone.0026230.g002
Table 1. Indexing of anti-fibrotic drugs from in vivo data.
Animal models Drugs
histological
score (DMN
alone) (Sc)
histological
score (with
drug) (St)
Ein vivo:
(Sc-St)xSc
DMN induced fibrosis (treatment) silymarin [40] 2 1.6 0.8
thalidomide [41] 1.56 0.89 1
tetrandrine [40] 2 1.3 1.4
colchicine [42] 3.8 2.3 5.7
CCl4 induced fibrosis (treatment) silymarin [43] 3.4 2.5 3.1
5-Pregnen-3b-ol-20-one-16a-carbonitrile (PCN) [44] 3.84 2.8 4
malotilate [45] 3.76 2.67 4.1
rosmarinic acid [43] 3.4 2.1 4.4
pioglitazone [46] 4 2.63 5.5
taurine [47] 3.33 1.33 6.7
CCl4 induced fibrosis (preventive) PCN [44] 3.6 3.68 20.3
taurine [48] 3.03 1.87 3.5
melatonin [49] 3.38 2.25 3.8
oxymatrine [50] 3.76 2.43 5
silymarin [51] 4 2.5 6
malotilate [45] 2.91 0.76 6.3
EGCG [52] 3.58 1.5 7.4
pioglitazone [46] 4 1.94 8.2
All data are taken from the literature using dimethylnitrosamine (DMN) treatment, carbon tetrachloride (CCl4) treatment, or CCl4 preventive fibrotic rat models.
Histological scores are linearly converted to a scale from 0 to 4. Ein vivo is established as shown. Drugs under each animal model are sorted according to increasing Ein vivo.
Silymarin, malotilate and pioglitazone have the same relative ranking in CCl4 treatment and preventive models.
doi:10.1371/journal.pone.0026230.t001
Ranking Anti-Fibrotic Drugs
PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e26230
correlation test [28] against Ein vivo from CCl4 fibrosis model. One
outlier was allowed in the analysis, as the sample size is relatively
small. The Spearman’s rank correlation coefficient rho ranges from
0 to 1, where 1 means perfect rank correlation (excluding the
outlier), and 0 means the opposite order. The optimized weight for
each marker was determined to be the value with the highest
frequency occurrence out of all cases which achieved rho=1 (Fig.
S2). High weight implies high importance of the marker towards a
strongly positive correlation. The optimized weights yielded the
following efficacy predictor (Epredict), computed as the linear
combination of the 10 optimized weights with the SAUC values:
Epredict~SAUCDHEzSAUCcollagen III
z2|SAUCmitochondrial membrane potential
z2|SAUCTIMP{1z2|SAUCpCREBz2|SAUCSmad3
A greater Epredict represents a higher drug efficacy and all negative
values were assigned to 0 as no efficacy. We also incorporated an
additional step to identify drugs with non-specific effects that cause
an increase in collagen expression (material S2 and Fig. S3); their
Epredict values were also assigned to 0 (Table 2). Fig. 3A shows that
the Epredict values had a good correlation with the Ein vivo from the
CCl4 treatment model, which was used for optimizing the weights.
Although the statistical approach used was to optimize the ranking
order of the drugs, a linear relationship was observed in the plot.
Taurine was found to be an outlier. Its relatively high in vivo
efficacy compared with the other drugs used in CCl4 treatment
model in Table 1 might be due to the much higher drug
concentration used in the study (1200 mg/kg daily) compared with
a typical drug concentration (,100 mg/kg daily) for the rest of the
drugs.
To validate that Epredict is a robust anti-fibrotic drug efficacy
predictor that can correlate with the in vivo data from other rodent
fibrosis models different from the training dataset; we tested the
ability of Epredict to correlate with two ‘‘blind’’ in vivo datasets. We
drew two additional correlation plots of Epredict against Ein vivo from
DMN treatment (Fig. 3B) and CCl4 preventive models (Fig. 3C).
Epredict was kept the same as computed for the CCl4 treatment
model. A positive correlation as well as a linear relationship
between Epredict and Ein vivo was again observed in both plots. To
further prove that this relationship does not depend on the choice
of the training set of data, similar results were obtained if DMN
treatment or CCl4 preventive models were used as the training
dataset instead of the CCl4 treatment model (data not shown).
Fig. 3D and E demonstrate how rho varies with the number of
markers and the number of cytological features, respectively. Both
curves reach a plateau before or at our experimental configuration
of 10 markers and 16 features per cell, showing that our study
design is sufficient for the anti-fibrotic correlation study. We next
test the robustness of the experimental configuration by shuffling
the weights in the Epredict formula; Fig. 3F shows the plot for the
percentage distribution of rho for all possible combinations of the 3
weights and 10 markers. There is a 23% chance of rho being equal
to 1, which is significantly higher than the random control (5%
chance of rho being equal to 1) in which the relative ranks were
randomized before applying the Spearman’s rank correlation test.
This demonstrates that a positive correlation between the in vitro
and in vivo indices can be achieved even if the optimized set of
weights is not used, implying that the weighting procedure of our
system is not vulnerable to high background noise. The in vitro
SAUCs have good predictive value alone, and the Epredict weighting
of the SAUCs optimizes their correlation and augments their
predictive power.
The in vivo histological scores can be estimated from Epredict
The linear relationship observed in all the three correlation plots
may be used to generate predictions of in vivo drug efficacies based
on in vitro measurements. Since all the in vivo data from long-term
drug treatment studies have been used either to build or validate
the in vitro-in vivo correlation, we now turn to short-term drug
treatment (,3-week treatment including single injection) as
another source of information for validating the predictive
capability of Epredict. One such study is available, concerning
sulfasalazine. We would like to use in vitro Epredict values generated
from HCA to predict in vivo histological scores. Since Epredict was
optimized with data from long-term studies, the predicted
histological scores should be similar to long-term drug treatment
outcomes. The histological scores from short-term studies are
expected to be slightly higher than our prediction, because
prolonging the treatment with the same drug used in the short-
term studies may further improve the fibrotic status and decrease
the histological scores.
The Epredict value of sulfasalazine is 39437; using the linear
relationship from the CCl4 treatment model (equation in Fig. 3A),
the Ein vivo value is calculated to be 5.8. Assuming the histological
score of rat livers with CCl4 induced fibrosis and no anti-fibrotic
treatment is 3.0 (same as in [29]), a long-term treatment with
sulfasalazine is predicted to reduce the fibrosis histological score to
1.1. A short-term study on rat CCl4 treatment model reported that
a single injection of sulfasalazine reduced the fibrosis score to 1.5
compared with 3.0 in untreated CCl4-only livers [29]. The results
agreed with our expectation, showing that the in vivo histological
scores can be estimated from Epredict.
High-efficacy drugs tend to target proliferation,
apoptosis and contractility of HSCs
All drugs were grouped into 3 categories based on their Epredict
values. The negative (n) group was defined to include all drugs
with Epredict equivalent to 0. Seven drugs with the highest Epredict
values were placed into the very positive (vp) group. The rest of the
drugs were in the positive (p) group. Before proceeding to
quantitative analysis, we firstly remark on some trends and
background about the categorized drugs. The n group has 16
drugs including 6 anti-oxidants, two HMG-CoA reductase
inhibitors, simvastatin and lovastatin, and all 4 non-specific
control compounds not related to fibrosis. Tranilast from the p
group showed anti-fibrotic effects in renal and liver fibrosis
[30,31], and it has a relatively high Epredict value of 19594. It has
been reported as a positive drug in another high-throughput
screening study [8]. In the vp group, glycyrrhizin, a herbal extract
from licorice, showed positive effects on patients with hepatitis C
[32]. Pioglitazone is another highly effective drug in the vp group
that has been subjected to multiple advanced stage clinical studies
[14]. It is one of the peroxisomal proliferator activated receptor
gamma ligands, which have overall higher efficacies on human
patients than colchicine, interferon gamma, and angiotensin
receptor blockers [15].
The mean KR values of the average intensity for fibrosis markers
were represented as boxplots for the n, p and vp groups of drugs
(Fig. 4A). Fewer outliers (red plus) were observed in the plot for the
vp group compared with that for all the drugs (n+p+vp), showing
that drugs with high efficacies have similar cellular effects and
probably have similar cellular targets.
A principal component analysis (PCA) was carried to detect the
set of markers that carry the most information, which could reflect
the importance of the underlying pathways. We found that the top
4 principal components built from SAUC values from drugs in the
vp group explained more than 95% of the cumulative variance in
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the system. The first principal component mainly captures
variation in DYm, which plays an important role in the apoptotic
pathway. The second principal component mainly captures
variations in caspase 3 (also apoptosis), collagen III (ECM),
MMP-2 (ECM) and TIMP-1 (ECM) (Fig. 4B). The three groups of
drugs with different levels of efficacy can be well separated when
mapped to the first, second and fourth principal component
coordinates (Fig. 4C). The vp group (blue) is found to have
relatively large values in the first, second and fourth principal
components; while the p group (black) has positive values in the
first principal component, but relatively low values in the second
principal component. These results showed that apoptosis is an
attractive anti-fibrotic target, while targeting ECM directly is also
effective. Interestingly DYm and caspase 3 did not co-vary with
each other in the first and second principal components,
suggesting that highly effective anti-fibrotic drugs target distinct
sub-pathways of apoptosis: either the intrinsic mitochondria-
dependent pathway, or caspase 3-dependent non-mitochondrial
pathways. As a result, multiple apoptotic markers are needed to
measure the effect of an anti-fibrotic drug on HSC apoptosis. In
addition, MMP-2 and TIMP-1 have expected roles in the PCA
analysis, being somewhat important, and often co-varying
inversely with each other.
To validate the finding that apoptosis is an attractive anti-
fibrotic target, the primary mechanism of action of each drug was
found from the literature (Table S5) and was broadly categorized
into 4 targets [33]. The target ‘‘cytokine’’ includes drugs targeting
cytokines such as TGF-b1 and PDGF activities; the target ‘‘ECM’’
includes drugs inhibiting collagen synthesis or promoting degra-
dation; the target ‘‘ROS’’ includes all anti-oxidants; and the target
‘‘HSCs’’ includes all other aspects including drugs targeting HSC
proliferation, apoptosis or contractility. Drugs were allowed to be
in 1 or multiple categories to account for the multiple signaling
pathways a drug may be involved in; however, secondary
mechanism of action (e.g. HCS apoptosis due to the anti-oxidative
activity of a drug) is not included. The results were summarized in
4-way Venn diagrams (Fig. 4D). The 49 drugs showed a balanced
distribution in each of the 4 categories. However, the more
effective drugs seem to have their primary effects on HSCs
directly, which agrees with the PCA result that the HSC apoptosis
pathway is a potent drug target.
Discussion
Suppressing collagen production or reducing HSC viability
represents an important anti-fibrotic drug screening strategy.
Single-parameter in vitro studies have relatively poor correlation
with in vivo drug efficacy; while multi-parameter in vitro studies are
easy to perform but difficult to interpret. In this paper, we take a
systematic statistical approach to the problem of correlating multi-
parameter HCA screening against published in vivo drug effects.
Our HCA system includes 10 fibrotic markers and 16 imaging
features per marker, which follow changes in reactive oxygen
species, TGF-b, proliferation, apoptosis, collagen regulation and
cell contractility. Using a limited subset of the in vivo literature, we
compute an optimized interpretation of the in vitro data, called
Epredict, to predict in vivo drug efficacy. Then we test the
performance of the Epredict values on two different subsets of the
in vivo literature. We find that Epredict is able to identify drugs with
anti-fibrotic effects, and also be able to distinguish drugs with
moderate and high efficacies.
Studies of in vitro-in vivo comparative efficacy can help select
promising categories of drugs to be given priority in the drug
discovery pipeline. However, it is challenging to perform such
Table 2. List of Epredict values for all the drugs.
Drugs Epredict
taxifolin 0
taurine 0
curcumin 0
resveratrol 0
silymarin 0
minoxidil sulphate 0
simvastatin 0
genistein 0
lovastatin 0
PTK787/ZK22258 (PTK/ZK) 0
Y27632 0
rotenone 0
AG1295 0
paclitaxel 0
aphidicolin 0
nocodazole 0
pentoxifylline 5175
matrine 5295
astragaloside IV 5496
thalidomide 6263
colchicine 6487
TGFb inhibitor V 6974
gliotoxin 7086
5-Pregnen-3b-ol-20-one-16a-carbonitrile (PCN) 8203
camostat mesylate 8231
imatinib mesylate 8454
oxymatrine 8528
pirfenidone 8837
minoxidil 9069
AG1296 9154
somatostatin 10057
MG132 10669
tetrandrine 10747
telmisartan 11467
malotilate 12941
melatonin 13728
fasudil HCl 14295
olmesartan medoxomil 15959
silybin 18138
TGFb inhibitor III 18315
tranilast 19594
epigallocatechin gallate (EGCG) 19704
bortezomib 21047
rosmarinic acid 21435
berberine chloride 21983
staurosporine 25015
glycyrrhizin 25728
pioglitazone 35226
sulfasalazine 39437
doi:10.1371/journal.pone.0026230.t002
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analysis from limited in vivo literature. The preclinical and clinical
results of many drugs are often lacking, incomplete or inconclu-
sive. Even when in vivo data is available, the histological scores may
not be assessed, while other serum markers such as ALT and AST
may not directly reflect fibrosis severity [34]. Another important
concern is the inter-observer variability by pathologists doing
histological examination of biopsy samples [35]. This intrinsic
baseline error seems to be well tolerated and low enough not to
mask the linear relationship between data from in vitro cell culture
and in vivo rat models in this study.
In this study the Epredict value was derived from HCA and a
limited training set of in vivo data, but its magnitude showed strong
positive correlation with most of the available in vivo scores from
fibrotic rat models, including blinded data sets that were reserved
for validation purposes. The level of the in vitro efficacy was
assessed by the overall effect of a drug on multiple pathways and
partially reflects the complex in vivo response. It is interesting to see
that a linear relationship with R2.0.9 exists between the in vitro
and in vivo data for CCl4 and DMN fibrotic treatment models;
while a weaker linear correlation (R2 = 0.54) was observed for the
Figure 3. Correlation between Epredict and Ein vivo. (A) Optimization of Epredict. Epredict is computed as a weighted combination of the features with
weights optimized using Spearman’s rank correlation test to best correlate with Ein vivo from the CCl4 treatment model. (B, C) Blind validations of in
vitro-in vivo correlation between Epredict and Ein vivo from two independent datasets containing DMN treatment and CCl4 preventive models
respectively. The linear relationship is highlighted using linear regression lines in all (A, B and C). The equations of the linear regression lines and the
R2 values are computed without considering the outliers in the graphs (i.e., taurine in A, colchicine in B and PCN in C). (D) The relationship between
the average rho value and the number of markers. (E) The relationship between average rho and the number of features per marker. Error bars
represent standard deviation. (F) The percentage distribution of rho is plotted for all possible combinations of the 3 weights and 10 markers. The
random control was done by randomizing the relative ranks of the in vivo drug efficacies for the Spearman’s rank correlation test.
doi:10.1371/journal.pone.0026230.g003
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Figure 4. Distinctive characteristics of the negative (n), positive (p), and very positive (vp) groups of drugs. (A) The average intensities
of the 10 makers for all drugs (n+p+vp), all positive (p+vp) drugs and the vp group of drugs are shown in the boxplots, where inter-quartile ranges are
represented by boxes. Whiskers represent 1.5 times the inter-quartile range and any data (outliers) beyond the whiskers are shown using red +. (B)
Principal component analysis (PCA) is done using data from the vp group. The top 4 principal components explain 95% of the cumulative variance in
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CCl4 preventive model. In the latter, fibrosis causing agents such
as CCl4 and drugs were given together to rats. As a result, many of
the drugs showing positive effects are protecting hepatocytes from
toxins or preventing HSC activation, rather than inducing fibrosis
regression. Since an activated HSC cell line is used in our
screening platform, it is more closely mimicking the treatment
model; hence a stronger linear relationship exists for both CCl4
and DMN treatment models. Furthermore, anti-oxidants work by
preventing HSC activation induced by free radicals. This group of
drugs can be considered preventive drugs, more than treatment
drugs, which agrees with our result that most of the anti-oxidants
have lower Epredict values.
The ability of cell culture models to predict in vivo drug effects is
limited by many fundamental constraints. For example, drugs
might be able to improve liver fibrosis by improving vascular flow
or liver architecture, such as the angiotensin II receptor
antagonists losartan and candesartan. Some drugs are metabolized
by hepatocytes into secondary compounds with different effects;
and such effects cannot be foreseen in vitro using HSC
monocultures. This study investigated the effects of drugs on
HSCs only. Our system is not suitable to substitute for animal
trials, but we recommend it for prioritizing the selection of drugs to
enter animal trials.
Interestingly, we have observed promising pieces of evidence that
the Epredict score can potentially be correlated with data from human
clinical trials. For example, the group of drugs with relatively high
Epredict scores (e.g. pioglitazone [36] and glycyrrhizin [37]) gave more
promising results in human clinical trials than the group of drugs
with low Epredict scores (e.g. colchicine [38] and silymarin [39]).
Furthermore, drugs with lower Epredict scores generally have fewer in
vivo publications than drugs with higher Epredict scores. Such
relationship may be partially due to the fact that the hepatic stellate
cell line used in this study is from human origin.
In conclusion, our anti-fibrotic drug screening platform is able
to index and rank drugs according to their in vitro efficacy. The in
vitro index system positively correlates with the in vivo histological
scores, which shows that our in vitro cell-based system has some
predictability of the in vivo drug response. Furthermore, drugs with
higher efficacies are found to exert their effects through directly
modulating HSC proliferation, apoptosis or contractility.
Supporting Information
Figure S1 Correlation between SAUC and Ein vivo for rat
CCl4 treatment model.
(TIF)
Figure S2 Pie charts showing the chance of occurrence
of weights in all cases where the Spearman’s rank
correlation coefficient rho achieves 1 for the training set
of data. The optimized weight for each marker is the value with
the highest occurrence indicated with a * in each pie chart, which
implies the relatively higher importance of the marker towards
contributing to a stronger positive correlation.
(TIF)
Figure S3 Images and quantification of hepatic stellate
cells LX-2 with collagen III immuno-fluorescence stain-
ing. Cells are treated with (A) pioglitazone, (B) EGCG, or (C)
aphidicolin at the indicated concentrations for 48 hours (blue:
nuclei; green: collagen III). The amount of collagen III in the
cytoplasmic region is quantified and represented as the percentage
of total collagen III intensity with respect to the control without
drug treatment. Error bars represent standard deviation from 2
replicate datasets.
(TIF)
Table S1 List of drugs and their highest working
concentrations.
(DOC)
Table S2 List of cellular features according to staining
sets. 10 fibrotic markers were studied using 7 staining sets. S1:
Cellomics BrdU cell proliferation kit (BrdU). S2: Cellomics
multiparameter apoptosis 1 kits (F-actin, mitochondrial membrane
potential, DYm). S3: Cellomics caspase 3 activation kit (caspase 3).
S4: Immunofluorescence staining of collagen III (collagen III). S5:
Immunofluorescence staining of MMP-2 and TIMP-1 (MMP-2,
TIMP-1). S6: Cellomics oxidative stress 1 kit (DHE). S7: Cellomics
Smad3 and phospho CREB activation kit (Smad3, pCREB). Ch1:
channel 1 for nuclear staining (blue). Ch2: channel 2 for protein
staining (red or green for two-channel images; green for three-
channel images). Ch3: channel 3 for protein staining (red for three-
channel images). The nuclear region is defined by the Ch1 object
mask. The cytoplasmic region that is positive for protein staining is
defined by Ch2 (or Ch3) object mask. Nuclei were stained in all 7
staining sets. Since nuclear features (features 1 to 5) are similar
regardless of the protein stainings in channel 2 and 3, they are only
considered once in S1. S1, S3, S4 and S6 were duble-stained with
one nuclear dye (Ch1) and one dye for a marker protein (Ch2).
They do not have features related to Ch3.
(DOC)
Table S3 List of references for the 10 markers of
fibrosis.
(DOC)
Table S4 List of papers with pathologist-graded histo-
logical scores on fibrotic rats from 1986 to 2009.
(DOC)
Table S5 Mechanisms of action of the drugs. All 49 drugs
are classified based on their mechanisms of action from the
literature.
(DOC)
Material S1 Computing Epredict from cellular feature
values.
(DOC)
Material S2 Method to identify drugs with non-specific
effects from in vitro HCA analysis.
(DOC)
the system. (Ci) All 49 drugs are mapped to the first and second principal component coordinates. Drugs in the gray box in (Ci) are mapped to the
second and fourth principal component coordinates in (Cii). The vp group (blue) is found to have relatively large values in the first, second and fourth
principal components; while the p group (black) has positive values in the first principal component, but relatively low values in the second principal
component. (D) All drugs (n+p+vp), all positive (p+vp) drugs and the vp group of drugs are classified into 4 categories according to their mechanisms
of action.
doi:10.1371/journal.pone.0026230.g004
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